DE602004026289D1 - Glutaminylcyclase-hemmer - Google Patents
Glutaminylcyclase-hemmerInfo
- Publication number
- DE602004026289D1 DE602004026289D1 DE602004026289T DE602004026289T DE602004026289D1 DE 602004026289 D1 DE602004026289 D1 DE 602004026289D1 DE 602004026289 T DE602004026289 T DE 602004026289T DE 602004026289 T DE602004026289 T DE 602004026289T DE 602004026289 D1 DE602004026289 D1 DE 602004026289D1
- Authority
- DE
- Germany
- Prior art keywords
- impaired
- inhibitors
- sleep
- regulation
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 title 1
- 230000001771 impaired effect Effects 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010062519 Poor quality sleep Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000037424 autonomic function Effects 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000037149 energy metabolism Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000003284 homeostatic effect Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46801403P | 2003-05-05 | 2003-05-05 | |
PCT/EP2004/004773 WO2004098591A2 (en) | 2003-05-05 | 2004-05-05 | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004026289D1 true DE602004026289D1 (de) | 2010-05-12 |
Family
ID=33435156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004026289T Expired - Lifetime DE602004026289D1 (de) | 2003-05-05 | 2004-05-05 | Glutaminylcyclase-hemmer |
Country Status (7)
Country | Link |
---|---|
US (2) | US7371871B2 (de) |
EP (1) | EP1620091B1 (de) |
JP (1) | JP4806628B2 (de) |
AT (1) | ATE462432T1 (de) |
DE (1) | DE602004026289D1 (de) |
WO (1) | WO2004098591A2 (de) |
ZA (1) | ZA200508439B (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087053A2 (en) | 2003-03-25 | 2004-10-14 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
KR20060009902A (ko) * | 2003-05-05 | 2006-02-01 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US8338120B2 (en) * | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
EP1506967B1 (de) | 2003-08-13 | 2007-11-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl Peptidase Inhibitoren. |
EP1699777B1 (de) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidylpeptidase-hemmer |
KR20120007079A (ko) | 2003-10-15 | 2012-01-19 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도 |
US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
ZA200603165B (en) * | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US20100099721A1 (en) * | 2003-11-03 | 2010-04-22 | Probiodrug Ag | Novel compounds for the treatment of neurological disorders |
DK1713780T3 (da) * | 2004-02-05 | 2012-05-07 | Probiodrug Ag | Hidtil ukendte inhibitorer af glutaminylcyklase |
CN1918131B (zh) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶抑制剂 |
BRPI0507905A (pt) * | 2004-02-20 | 2007-07-10 | Novartis Ag | uso de compostos orgánicos |
GEP20094679B (en) * | 2004-03-15 | 2009-05-10 | Takeda Pharmaceuticals Co | Dipeptidyl peptidase inhibitors |
US8110595B2 (en) | 2004-06-17 | 2012-02-07 | Cytokinetics, Inc. | Ureas and their use in the treatment of heart failure |
FR2873368B1 (fr) * | 2004-07-26 | 2008-01-04 | Merck Sante Soc Par Actions Si | Derives de guanidine et leurs utilisations en therapeutique |
JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
CN101277949A (zh) | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
US7713521B2 (en) * | 2005-08-12 | 2010-05-11 | Schering Corporation | MCP1 fusions |
EP2073810B1 (de) * | 2006-09-13 | 2011-08-31 | Takeda Pharmaceutical Company Limited | Verwendung von 2-6-(3-amin-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluor-benzonitril zur behandlung von diabetes, krebs, autoimmunerkrankungen und hiv-infektionen |
MY147393A (en) | 2005-09-14 | 2012-11-30 | Takeda Pharmaceutical | Administration of dipeptidyl peptidase inhibitors |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
ES2419007T3 (es) * | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
EP1962852B1 (de) * | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Verbindungen, zusammensetzungen und verfahren |
JP2007169167A (ja) * | 2005-12-19 | 2007-07-05 | Shiseido Co Ltd | Ce形成・成熟化剤、不全角化阻害剤、皮膚バリアー機能回復促進剤およびスキンケア用皮膚外用組成物 |
US7572614B2 (en) * | 2006-02-24 | 2009-08-11 | Academia Sinica | Crystal structure of soluble glutaminyl cyclase |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
MEP27308A (en) | 2006-04-11 | 2010-06-10 | Arena Pharm Inc | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
US7728146B2 (en) | 2006-04-12 | 2010-06-01 | Probiodrug Ag | Enzyme inhibitors |
US8324383B2 (en) * | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US9277737B2 (en) | 2006-09-21 | 2016-03-08 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the QPCTL-gene |
US8889709B2 (en) * | 2006-09-21 | 2014-11-18 | Probiodrug Ag | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions |
WO2008034891A2 (en) | 2006-09-21 | 2008-03-27 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
US8420684B2 (en) * | 2006-11-09 | 2013-04-16 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
JP5599614B2 (ja) * | 2006-11-09 | 2014-10-01 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
JP5379692B2 (ja) * | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
WO2008055947A1 (en) * | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
JP2010516235A (ja) * | 2007-01-19 | 2010-05-20 | プロビオドルグ エージー | アルツハイマー病及び他のqpct関連障害の治療のためのインビボスクリーニングモデル |
NZ579310A (en) | 2007-03-01 | 2012-03-30 | Probiodrug Ag | Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof |
EA201400366A1 (ru) * | 2007-03-01 | 2014-08-29 | Пробиодруг Аг | Новое применение ингибиторов глутаминилциклазы |
GB2447017A (en) * | 2007-03-01 | 2008-09-03 | Probiodrug Ag | New use for inhibitors of glutaminyl peptide cyclotransferinase |
DK2118101T3 (da) * | 2007-03-09 | 2013-01-02 | Probiodrug Ag | IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer |
US8093236B2 (en) * | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
WO2008128982A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
JP5675340B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | 新規阻害剤 |
DK2142514T3 (da) * | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
EP2142515B1 (de) * | 2007-04-18 | 2014-03-26 | Probiodrug AG | Nitrovinyl-diamin derivate als glutaminyl cyclase hemmer |
DK2160380T3 (da) * | 2007-04-18 | 2014-06-30 | Probiodrug Ag | Cyano-guanidin derivater som glutaminyl cyclase inhibitorer |
EP2146968B1 (de) * | 2007-04-18 | 2015-09-23 | Probiodrug AG | Harnstoffderivate als inhibitoren von glutaminylcyclase |
JP5676249B2 (ja) * | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
NZ583799A (en) * | 2007-09-12 | 2011-12-22 | Probiodrug Ag | Transgenic mice comprising a DNA transgene encoding ABeta peptide |
CA2710494A1 (en) * | 2008-01-14 | 2009-07-23 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
EP2108960A1 (de) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY |
EP3338795A1 (de) * | 2008-07-21 | 2018-06-27 | Probiodrug AG | Diagnostischer antikörpertest |
EP2344158B1 (de) * | 2008-09-04 | 2017-12-27 | Probiodrug AG | Verwendung von isoqc-inhibitoren |
JP5707327B2 (ja) * | 2008-09-04 | 2015-04-30 | プロビオドルグ エージー | 新規の阻害剤 |
US20100144140A1 (en) * | 2008-12-10 | 2010-06-10 | Novellus Systems, Inc. | Methods for depositing tungsten films having low resistivity for gapfill applications |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
SG182615A1 (en) | 2010-02-18 | 2012-08-30 | Probiodrug Ag | Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase |
EP2542549B1 (de) * | 2010-03-03 | 2016-05-11 | Probiodrug AG | Glutaminylcyclase-hemmer |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
DK2606129T3 (en) | 2010-08-19 | 2015-06-29 | Probiodrug Ag | Glutaminyl cyclase crystal structure |
JP6026425B2 (ja) * | 2010-11-02 | 2016-11-16 | プロビオドルグ エージー | イソグルタミニルシクラーゼの結晶構造 |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
AU2013292519B2 (en) | 2012-07-19 | 2017-12-07 | Drexel University | Sigma receptor ligands for modulating cellular protein homeostasis |
CN107141266B (zh) * | 2017-06-28 | 2019-04-09 | 佳木斯大学附属第一医院 | 一种用于治疗阿尔茨海默病的杂环化合物及其制备方法 |
PL3658141T3 (pl) | 2017-07-24 | 2023-06-12 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47 |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
EP3886854A4 (de) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung |
CN110590801B (zh) * | 2019-09-05 | 2020-11-03 | 中国药科大学 | 谷氨酰胺酶小分子荧光探针及其制备方法和用途 |
JP2024523552A (ja) | 2021-06-24 | 2024-06-28 | インシリコ メディシン アイピー リミテッド | 疾患の処置のためのベータ-ラクタム誘導体 |
Family Cites Families (233)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2961377A (en) * | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3879541A (en) * | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
DE2009743A1 (de) | 1970-03-03 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Substituierte Biguanide mit antihyperglykämischer Wirkung |
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
CH602612A5 (de) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
JPS605593B2 (ja) | 1981-03-20 | 1985-02-12 | 北興化学工業株式会社 | イミダゾ−ル誘導体および農園芸用殺菌剤 |
JPS6137764A (ja) | 1984-07-31 | 1986-02-22 | Suntory Ltd | 抗プロリルエンドペプチダ−ゼ活性を有する新規生理活性化合物 |
JPH0623190B2 (ja) | 1985-04-16 | 1994-03-30 | サントリー株式会社 | インヒビタ−活性を有するn−アシルピロリジン誘導体及びその製法並びに用途 |
US4873342A (en) | 1985-04-16 | 1989-10-10 | Suntory Limited | Dipeptide derivative and synthesis and use thereof |
CA1298033C (en) | 1985-04-16 | 1992-03-24 | Takaharu Tanaka | Dipeptide derivative of fatty acid |
JPS62114957A (ja) | 1985-11-13 | 1987-05-26 | Suntory Ltd | プロリルエンドペプチダ−ゼ阻害作用を有する新規ピロリジン誘導体およびその製法並びに用途 |
JPH0714878B2 (ja) | 1985-11-14 | 1995-02-22 | サントリー株式会社 | ピロリジンアミドを有効成分とするプロリルエンドペプチダーゼ阻害剤 |
JPH0764834B2 (ja) | 1985-11-29 | 1995-07-12 | サントリー株式会社 | プロリルエンドペプチダーゼ阻害活性を有する新規ピロリジンアミド誘導体およびその製法並びに用途 |
CA1320734C (en) | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
US5198458A (en) | 1986-02-04 | 1993-03-30 | Suntory Limited | Pyrrolidineamide derivatives of acylamino acid and pharmaceutical composition containing the same |
JPH08806B2 (ja) | 1986-11-18 | 1996-01-10 | サントリー株式会社 | プロリルエンドペプチダ−ゼ阻害作用を有する新規ピロリジンアミド誘導体 |
US5254550A (en) | 1986-11-20 | 1993-10-19 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
ES2058089T3 (es) | 1986-11-20 | 1994-11-01 | Ono Pharmaceutical Co | Un procedimiento para la preparacion de un nuevo derivado de prolinal. |
JPS63162672A (ja) | 1986-12-25 | 1988-07-06 | Ono Pharmaceut Co Ltd | 新規なプロリナ−ル誘導体、それらの製造方法およびそれらを含有する抗健忘症剤 |
ES2046195T3 (es) | 1986-12-29 | 1994-02-01 | Ono Pharmaceutical Co., Ltd. | Un procedimiento para la preparacion de los derivados de prolinal. |
US5262431A (en) | 1986-12-29 | 1993-11-16 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
JPH089591B2 (ja) | 1986-12-29 | 1996-01-31 | 小野薬品工業株式会社 | 新規なプロリナール誘導体 |
ES2054712T3 (es) | 1987-02-04 | 1994-08-16 | Ono Pharmaceutical Co | Un procedimiento para la preparacion de los derivados de prolinal. |
JP2528343B2 (ja) | 1987-02-04 | 1996-08-28 | 小野薬品工業株式会社 | 新規なプロリナ―ル誘導体 |
DE3855875T2 (de) | 1987-02-23 | 1997-08-28 | Ono Pharmaceutical Co | Thiazolidin-Derivate |
DE3712365A1 (de) | 1987-04-11 | 1988-10-27 | Hoechst Ag | Neue 2-acylpyrrolidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel sowie deren verwendung |
JPS6442465A (en) | 1987-08-07 | 1989-02-14 | Wakunaga Pharma Co Ltd | N-acylprolylpyrrolidine derivative, production and use thereof |
JP2649237B2 (ja) | 1988-03-07 | 1997-09-03 | キッセイ薬品工業 株式会社 | チアゾリジン誘導体 |
US4857524A (en) | 1987-08-08 | 1989-08-15 | Kissei Pharmaceutical Co., Ltd. | Thiazolidine compounds and therapeutic method |
JP2515558B2 (ja) | 1987-09-10 | 1996-07-10 | 株式会社ヤクルト本社 | 新規なペプチドおよびそれを有効成分とする抗健忘症剤 |
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
JPH0742309B2 (ja) | 1987-11-30 | 1995-05-10 | キッセイ薬品工業株式会社 | チアゾリジン誘導体 |
JPH01250370A (ja) | 1987-12-23 | 1989-10-05 | Zeria Pharmaceut Co Ltd | 新規アミノ酸イミド誘導体、製法ならびに用途 |
US5053414A (en) | 1988-04-08 | 1991-10-01 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
US5328899A (en) | 1988-07-15 | 1994-07-12 | The Salk Institute For Biological Studies | NPY peptide analogs |
ZA896376B (en) | 1988-08-26 | 1990-05-30 | Merrell Dow Pharma | Neuropeptide y agonists |
ZA896374B (en) | 1988-08-26 | 1990-05-30 | Merrell Dow Pharma | Neuropeptide y antagonists |
JP2531989B2 (ja) | 1988-09-14 | 1996-09-04 | 吉富製薬株式会社 | ピリジン化合物 |
CA2004028C (en) | 1988-12-08 | 1998-09-22 | Motoki Torizuka | Condensed benzene derivative |
US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
JPH02207070A (ja) | 1989-02-07 | 1990-08-16 | Zeria Pharmaceut Co Ltd | アミノ酸イミド誘導体、それを含有する医薬及び該化合物の製造中間体 |
JP2691442B2 (ja) | 1989-02-20 | 1997-12-17 | 株式会社ヤクルト本社 | 新規なプロリン誘導体 |
WO1990012005A1 (en) | 1989-04-13 | 1990-10-18 | Japan Tobacco Inc. | New amino acid derivatives having prolylendopeptidase inhibitor activity |
JPH0331298A (ja) | 1989-06-28 | 1991-02-12 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
JPH07103101B2 (ja) | 1989-07-24 | 1995-11-08 | キッセイ薬品工業株式会社 | ピログルタミン酸誘導体 |
JPH082869B2 (ja) | 1989-07-24 | 1996-01-17 | キッセイ薬品工業株式会社 | 健忘症治療剤およびプロリン誘導体 |
JPH0776211B2 (ja) | 1989-07-24 | 1995-08-16 | キッセイ薬品工業株式会社 | ピログルタミン酸誘導体 |
JPH082791B2 (ja) | 1989-07-24 | 1996-01-17 | キッセイ薬品工業株式会社 | 健忘症治療剤 |
DD296075A5 (de) | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
DE3939797A1 (de) | 1989-12-01 | 1991-06-06 | Basf Ag | Neue vom neuropeptid y abgeleitete peptide |
WO1991011457A1 (en) | 1990-01-24 | 1991-08-08 | Buckley Douglas I | Glp-1 analogs useful for diabetes treatment |
JPH04211648A (ja) | 1990-07-27 | 1992-08-03 | Nippon Kayaku Co Ltd | ケト酸アミド誘導体 |
JPH03255080A (ja) | 1990-03-05 | 1991-11-13 | Yoshitomi Pharmaceut Ind Ltd | ベンゼン化合物 |
US5073549A (en) | 1990-03-22 | 1991-12-17 | Bristol-Myers Squibb Company | BU-4164E - A and B, prolyl endopeptidase inhibitors and their methods of use |
US4999349A (en) | 1990-03-22 | 1991-03-12 | Bristol-Myers Squibb Co. | BU-4164E - A and B, prolyl endopeptidase inhibitors |
CA2080474A1 (en) | 1990-04-14 | 1991-10-15 | William W. Bachovchin | Inhibitors of dipeptidyl-aminopeptidase type iv |
US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
JPH049367A (ja) | 1990-04-26 | 1992-01-14 | Zeria Pharmaceut Co Ltd | アリールアルカノイル誘導体,該化合物の製造中間体及びそれらを含有する医薬 |
US5077409A (en) * | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
US6517824B1 (en) * | 1990-05-14 | 2003-02-11 | University Of Medicine & Denistry Of New Jersey | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
WO1991017767A1 (en) | 1990-05-21 | 1991-11-28 | New England Medical Center Hospitals, Inc. | Method of treating inhibition of dipeptidyl aminopeptidase type iv |
JP2511605B2 (ja) | 1990-06-04 | 1996-07-03 | ファイザー・インコーポレーテッド | 芳香性ピロリジンおよびチアゾリヂンアミド類 |
US5407950A (en) | 1990-06-07 | 1995-04-18 | Zeria Pharmaceutical Co., Ltd. | Arylalkanoylamine derivative and drug containing the same |
EP0468469A2 (de) | 1990-07-27 | 1992-01-29 | Japan Tobacco Inc. | Prolinderivate |
JPH07108897B2 (ja) | 1990-07-27 | 1995-11-22 | 日本たばこ産業株式会社 | 新規なプロリン誘導体 |
US5506256A (en) | 1990-07-27 | 1996-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Proline derivatives possessing prolyl endopeptidase-inhibitory activity |
JPH05186498A (ja) | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
JPH04235162A (ja) | 1990-08-09 | 1992-08-24 | Zeria Pharmaceut Co Ltd | 新規コハク酸アミド誘導体およびそれを含有する医薬 |
JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
JPH0819154B2 (ja) | 1991-03-14 | 1996-02-28 | 江崎グリコ株式会社 | ジペプチジルカルボキシペプチダーゼを阻害するペプチド |
JPH04334357A (ja) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
EP0553357B1 (de) | 1991-06-20 | 1997-09-10 | Snow Brand Milk Products Co., Ltd. | Neuartige prolyl-endopeptidase-inhibitoren sna-115 und sna-115t, ihre herstellung, und hierbei verwendete stämme |
JP3010795B2 (ja) | 1991-07-04 | 2000-02-21 | 不二製油株式会社 | ペプチドの苦味除去方法 |
GB9115740D0 (en) | 1991-07-20 | 1991-09-04 | Smithkline Beecham Plc | Medicaments |
CA2121369C (en) | 1991-10-22 | 2003-04-29 | William W. Bachovchin | Inhibitors of dipeptidyl-aminopeptidase type iv |
CA2126212A1 (en) | 1991-12-19 | 1993-07-08 | Albert Tseng | A novel molecule which inhibits neuropeptide tyrosine biological function |
JPH05301826A (ja) | 1991-12-24 | 1993-11-16 | Snow Brand Milk Prod Co Ltd | プロリルエンドペプチダーゼ阻害剤 |
JPH05201970A (ja) | 1992-01-24 | 1993-08-10 | Japan Tobacco Inc | 新規プロリン誘導体 |
CA2133461A1 (en) | 1992-04-01 | 1993-10-14 | Graham J. Durant | 4-[4'piperidinyl or 3'-pirrolidinyl] substituted imidazoles as h3-receptor antagonists and therapeutic uses thereof |
JP3318622B2 (ja) | 1992-05-27 | 2002-08-26 | 独立行政法人産業技術総合研究所 | プロリルエンドペプチダーゼ阻害剤 |
GB9213215D0 (en) | 1992-06-20 | 1992-08-05 | Wellcome Found | Peptides |
IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
JPH06116284A (ja) | 1992-10-02 | 1994-04-26 | Yamanouchi Pharmaceut Co Ltd | 新規ペプチド |
FR2696740B1 (fr) | 1992-10-13 | 1994-12-30 | Dospharma Sa | Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments. |
WO1994012474A1 (en) | 1992-11-20 | 1994-06-09 | Japan Tobacco Inc. | Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof |
JPH06192298A (ja) | 1992-12-24 | 1994-07-12 | Mitsui Toatsu Chem Inc | 新規機能性ペプチド |
DE4326465A1 (de) | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JPH06234693A (ja) | 1993-02-09 | 1994-08-23 | Snow Brand Milk Prod Co Ltd | 新規イソテトラセノン系物質及びその製造法 |
FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
FR2703050B1 (fr) | 1993-03-24 | 1995-04-28 | Adir | Nouveaux dérivés bicycliques azotés, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
JPH11501281A (ja) | 1993-06-18 | 1999-02-02 | ユニバーシティ オブ シンシナティ | 神経ペプチドyアンタゴニスト及びアゴニスト |
WO1995001352A1 (fr) | 1993-06-30 | 1995-01-12 | Zeria Pharmaceutical Co., Ltd. | Derive de thiazolidine et medicament le contenant |
US5756763A (en) | 1993-07-23 | 1998-05-26 | Zaidan Hojin Biseibutsu Kagaku Kenkyukai | Pyrrolidine derivatives |
WO1995011689A1 (en) | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
CA2177821C (en) | 1993-12-02 | 2000-03-28 | Norton P. Peet | Prolyl endopeptidase inhibitors |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
EP0658568A1 (de) | 1993-12-09 | 1995-06-21 | Eli Lilly And Company | Glucagon-ähnliche, insalinotrope Peptide, ihre Zusammensetzungen und ihre Herstellungsverfahren |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
AU1891295A (en) | 1994-02-22 | 1995-09-04 | Knoll Aktiengesellschaft | Use of 1-(arylalkylaminoalkyl) imidazoles for treating neurological damage |
JPH07267988A (ja) | 1994-03-31 | 1995-10-17 | Yamanouchi Pharmaceut Co Ltd | 新規ペプチド |
US5435493A (en) * | 1994-04-21 | 1995-07-25 | J. Houle Et Fils Inc. | Manure distributor with atop discharge pipes and manure spreader incorporating the same |
US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
EP0716854A3 (de) | 1994-10-20 | 1996-08-28 | Lilly Co Eli | Zusammensetzungen zur Inhibierung von Neuropeptid Y |
US5663192A (en) | 1994-10-20 | 1997-09-02 | Eli Lilly And Company | Heterocyclic neuropeptide Y receptor antagonists |
GB9500601D0 (en) | 1995-01-12 | 1995-03-01 | Wellcome Found | Modified peptides |
US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
US6448282B1 (en) * | 1995-05-30 | 2002-09-10 | Gliatech, Inc. | 1H-4(5)-substituted imidazole derivatives |
IL117997A0 (en) | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
US5668151A (en) | 1995-06-07 | 1997-09-16 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
US5635503A (en) | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Company | Dihydropyridine npy antagonists: piperazine derivatives |
US5554621A (en) | 1995-06-07 | 1996-09-10 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives |
JP3727383B2 (ja) | 1995-07-31 | 2005-12-14 | 月桂冠株式会社 | プロリルエンドペプチダーゼ阻害剤 |
TR199700334T1 (tr) | 1995-09-01 | 1997-08-21 | Lilly Co Eli | Indolil nöropeptid y reseptör antagonistleri. |
DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19544685A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19544686A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
JPH09157253A (ja) | 1995-12-12 | 1997-06-17 | Yamanouchi Pharmaceut Co Ltd | 新規アミノ酸誘導体 |
EP0871442A1 (de) | 1996-01-09 | 1998-10-21 | Eli Lilly And Company | Benzimidzolyl neuropeptidy rezeptor antagonisten |
US5662723A (en) | 1996-03-22 | 1997-09-02 | Libbey Glass Inc. | Apparatus and method for forming a decorative pattern on glassware having an edge |
EP0893442B1 (de) | 1996-03-28 | 2005-01-12 | Shionogi & Co., Ltd. | Durch lymphe absorbierbare imidazolderivate |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
EP0912551A1 (de) | 1996-05-14 | 1999-05-06 | Novo Nordisk A/S | Somatostatin-agonisten und -antagonisten |
AU3224997A (en) | 1996-05-29 | 1998-01-05 | Prototek, Inc | Prodrugs of thalidomide and methods for using same as modulators of t-cell function |
EP1007073A4 (de) | 1996-06-04 | 2002-03-27 | Synaptic Pharma Corp | Verfahren zur änderung der essgewohnheiten, für diese verfahren geeignete verbindungen, sowie eine für einen hypothalamisches atypisches neuropeptid y/ peptide yy rezeptor kodierende dna |
WO1998003492A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
US6133265A (en) | 1996-07-23 | 2000-10-17 | Neurogen Corporation | Certain amido- and amino- substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
EP0915860A1 (de) | 1996-07-23 | 1999-05-19 | Neurogen Corporation | Einige amido- und ammo-substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande |
US6849733B1 (en) | 1996-08-23 | 2005-02-01 | Agouron Pharmaceuticals, Inc. | Neuropeptide-Y ligands |
US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
JP3880664B2 (ja) | 1996-09-04 | 2007-02-14 | 月桂冠株式会社 | プロリルエンドペプチダーゼ阻害ペプチド |
US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
AR016751A1 (es) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
SE9703414D0 (sv) | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
WO1999020599A1 (en) | 1997-10-21 | 1999-04-29 | Cambridge Neuroscience, Inc. | Pharmaceutically active compounds and methods of use |
CA2319195A1 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
US5994379A (en) | 1998-02-13 | 1999-11-30 | Merck Frosst Canada, Inc. | Bisaryl COX-2 inhibiting compounds, compositions and methods of use |
CA2320091A1 (en) | 1998-02-13 | 1999-08-19 | Dr. Willmar Schwabe Gmbh & Co. | Stable hyperforin salts, methods of manufacturing them, and their use for the treatment of alzheimer's disease |
EP1062222A1 (de) | 1998-03-09 | 2000-12-27 | Fondatech Benelux N.V. | Serin-peptidase modulatoren |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
AU765370B2 (en) | 1998-06-05 | 2003-09-18 | Point Therapeutics, Inc. | Cyclic boroproline compounds |
IL140197A0 (en) | 1998-06-12 | 2002-02-10 | Sod Conseils Rech Applic | β-CARBOLINE COMPOUNDS |
DE19826972A1 (de) | 1998-06-18 | 1999-12-23 | Univ Magdeburg Tech | Verwendung von Enzyminhibitoren und pharmazeutische Zubereitung zur Therapie von dermatologischen Erkrankungen mit follikulären und epidermalen Hyperkeratosen und einer verstärkten Keratinozytenproliferation |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
EP1092046A4 (de) | 1998-07-02 | 2003-02-19 | Invitro Diagnostics Inc | Verfahren, zusammensetzngen und apparat zur herstellung von nukleinsäuremolekülen mit selektiver affinität für ein zielmolekül |
DE19834610A1 (de) | 1998-07-31 | 2000-02-24 | Probiodrug Ges Fuer Arzneim | Mechanismus-orientierte Inhibitoren der Dipeptidyl Peptidase I |
EP1306091A3 (de) | 1998-07-31 | 2003-05-21 | Novo Nordisk A/S | Stimulation der Beta-Zellen Vermehrung |
DE19834591A1 (de) * | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
BR9913153A (pt) | 1998-08-21 | 2001-05-15 | Point Therapeutics Inc | Normalização da atividade do substrato |
WO2000030674A1 (en) | 1998-11-26 | 2000-06-02 | Ferring Bv | Neuropeptide y y4 agents in the treatment of reproductive disorders |
WO2000053171A1 (en) | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
US6211182B1 (en) | 1999-03-08 | 2001-04-03 | Schering Corporation | Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms |
ES2225107T3 (es) | 1999-03-29 | 2005-03-16 | Uutech Limited | Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes. |
US6121311A (en) | 1999-04-28 | 2000-09-19 | Japan Tobacco Inc. | Method for treating cocainism |
EP1177172A1 (de) | 1999-05-05 | 2002-02-06 | Ortho-McNeil Pharmaceutical, Inc. | 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derivate als ligande von neuropeptide y rezeptoren zur behandlung der fettleibigkeit und andere störungen |
FR2793638A1 (fr) | 1999-05-12 | 2000-11-17 | Ascom Monetel Sa | Systeme d'alimentation a partir d'une ligne telephonique |
JP3148739B2 (ja) | 1999-05-19 | 2001-03-26 | ドーマー株式会社 | プロリルエンドペプチダーゼ阻害剤 |
US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
GB9917909D0 (en) | 1999-07-31 | 1999-09-29 | Synphar Lab Inc | Cysteine protease inhibitors |
DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
JP2003535034A (ja) | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法 |
GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
AU2001228309A1 (en) | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
US7064145B2 (en) * | 2000-02-25 | 2006-06-20 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
DE60042585D1 (de) | 2000-02-29 | 2009-09-03 | Univ Firenze | 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6605589B1 (en) * | 2000-03-31 | 2003-08-12 | Parker Hughes Institute | Cathepsin inhibitors in cancer treatment |
WO2001072290A2 (en) * | 2000-03-31 | 2001-10-04 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
PL360856A1 (en) | 2000-07-04 | 2004-09-20 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
US20020042400A1 (en) * | 2000-08-17 | 2002-04-11 | Yajing Rong | Novel alicyclic imidazoles as H3 agents |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20030013177A1 (en) | 2001-05-23 | 2003-01-16 | Ebens Allen J. | Polynucleotides encoding insect glutaminyl cyclase and uses thereof |
DE60224189T2 (de) | 2001-06-20 | 2008-12-11 | Merck & Co., Inc. | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
ES2257555T3 (es) | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
ZA200300833B (en) | 2001-06-27 | 2004-02-10 | Probiodrug Ag | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents. |
US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
ES2339813T3 (es) | 2001-06-27 | 2010-05-25 | Glaxosmithkline Llc | Fluoropirrolidinas como inhibidores de dipeptidil peptidasas. |
US7196201B2 (en) | 2001-06-27 | 2007-03-27 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
ES2291477T3 (es) | 2001-06-27 | 2008-03-01 | Smithkline Beecham Corporation | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. |
DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
CA2418543A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
JP2005502624A (ja) | 2001-07-03 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | 糖尿病を治療するための、dpp−ivを阻害するプリン誘導体 |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
KR20040033048A (ko) | 2001-09-14 | 2004-04-17 | 미츠비시 웰파마 가부시키가이샤 | 티아졸리딘 유도체 및 이의 약학적 용도 |
WO2003024965A2 (en) | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
EP2316470A3 (de) | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetikuminhibitoren von post-Prolin-spaltenden Enzymen |
AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
ES2252656T3 (es) | 2002-02-13 | 2006-05-16 | F. Hoffmann-La Roche Ag | Nuevos derivados de piridina y quinolina. |
PL371678A1 (en) | 2002-02-13 | 2005-06-27 | F.Hoffmann-La Roche Ag | Novel pyridin- and pyrimidin-derivatives |
BR0307735A (pt) * | 2002-02-19 | 2005-01-25 | Upjohn Co | Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença |
HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
EP1490335B1 (de) | 2002-03-25 | 2007-09-19 | Merck & Co., Inc. | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes |
EP1513808A2 (de) | 2002-06-04 | 2005-03-16 | Pfizer Products Inc. | Fluorierte zyklische amide als dipeptidylpeptidase-iv inhibitoren |
WO2003101449A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
AU2003241960B2 (en) | 2002-06-06 | 2009-07-30 | Eisai R&D Management Co., Ltd. | Novel fused imidazole derivative |
WO2004007446A1 (ja) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | 新規なアゼチジン誘導体又はその塩 |
US7208498B2 (en) | 2002-07-15 | 2007-04-24 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
CN105001222B (zh) | 2002-08-21 | 2017-11-07 | 勃林格殷格翰制药两合公司 | 8‑[3‑氨基‑哌啶‑1‑基]‑黄嘌呤化合物,其制备方法及作为药物制剂的用途 |
DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE60315336T2 (de) | 2002-09-19 | 2008-05-08 | Abbott Laboratories, Abbott Park | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren der dipeptidyl peptidase iv (dpp-iv) |
CA2521907A1 (en) * | 2003-04-10 | 2004-10-21 | Pfizer Inc. | Bicyclic compounds as nr2b receptor antagonists |
DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
EP1622870A2 (de) * | 2003-05-05 | 2006-02-08 | Prosidion Ltd. | Glutaminylbasierte dp-iv-inhibitoren |
KR20120007079A (ko) * | 2003-10-15 | 2012-01-19 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도 |
ZA200603165B (en) * | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
CN1918131B (zh) * | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶抑制剂 |
-
2004
- 2004-05-05 DE DE602004026289T patent/DE602004026289D1/de not_active Expired - Lifetime
- 2004-05-05 US US10/838,993 patent/US7371871B2/en active Active
- 2004-05-05 EP EP04731158A patent/EP1620091B1/de not_active Expired - Lifetime
- 2004-05-05 AT AT04731158T patent/ATE462432T1/de active
- 2004-05-05 ZA ZA200508439A patent/ZA200508439B/xx unknown
- 2004-05-05 WO PCT/EP2004/004773 patent/WO2004098591A2/en active Application Filing
- 2004-05-05 JP JP2006505375A patent/JP4806628B2/ja not_active Expired - Fee Related
-
2008
- 2008-03-12 US US12/046,520 patent/US7655684B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US7371871B2 (en) | 2008-05-13 |
US20040224875A1 (en) | 2004-11-11 |
EP1620091A2 (de) | 2006-02-01 |
JP4806628B2 (ja) | 2011-11-02 |
ATE462432T1 (de) | 2010-04-15 |
ZA200508439B (en) | 2007-03-28 |
EP1620091B1 (de) | 2010-03-31 |
WO2004098591A3 (en) | 2005-03-31 |
US7655684B2 (en) | 2010-02-02 |
US20080153892A1 (en) | 2008-06-26 |
JP2006525276A (ja) | 2006-11-09 |
WO2004098591A2 (en) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004026289D1 (de) | Glutaminylcyclase-hemmer | |
WO2005075436A3 (en) | Novel inhibitors of glutaminyl cyclase | |
ECSP066336A (es) | Derivados de 3-amino croman y 2-amino tetralin | |
MA35285B1 (fr) | Indazoles | |
EA200802054A1 (ru) | Ингибиторы фермента | |
PT2139334E (pt) | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos | |
ZA200608628B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
WO2007009083A3 (en) | Compounds with activity at retinoic acid receptors | |
MX2007012374A (es) | Metodos y composiciones para el tratamiento de condiciones relacionadas con cns. | |
NO20083197L (no) | Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese | |
IL189298A0 (en) | 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission | |
FR2871359B1 (fr) | Regulateur de temperature de contact avec le patient d'une mammographie | |
ZA200705018B (en) | Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease | |
TW200510365A (en) | Benzopyran compounds useful for treating inflammatory conditions | |
EP2604602A4 (de) | Heteroarylpyrazolderivat | |
SE0401465D0 (sv) | New substituted piperdines as modulators of dopamine neurotransmission | |
MA31567B1 (fr) | Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique | |
WO2005099702A3 (en) | R(-)-11-hydroxyaporphine derivatives and uses thereof | |
DE602005000676D1 (de) | Triazacyclopentaäcdüindenderivate | |
TW200504045A (en) | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | |
ATE541835T1 (de) | Neue inhibitoren von glutaminylcyclase | |
IL174726A0 (en) | Transgenic animals with serious disorders related to alzheimer's disease | |
DE602007013079D1 (de) | Phthalazin-, aza- und diazaphthalazinverbindungen und anwendungsverfahren | |
MX2008001200A (es) | Derivados de acido 2-hidroxi-propionico y derivados de 3-hidroxi-benzofura-2-ona con afinidad para el receptor gaba-b. | |
FR2887539B1 (fr) | Bio reacteur, pour le traitement des effluents par chenal d'aeration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |